NEWS

Medicines Development places Development Manager at Immuron.

May 6, 2012

Medicines Development and Immuron are pleased to announce that Gerhard Rank has joined Immuron as Development Manager under the Development Manager training and placement initiative supported by the Victorian Government’s Smart SME’s Innovation and Commercialisation Program.

While remaining an employee of Medicines Development, Gerhard will be a part of the Immuron team to progress the development of their novel oral immunotherapy platform. In addition to Gerhard’s practical, hands on planning and implementation of the development program, the broader Medicines Development will provide Immuron with operational advice and support to supplement their significant in-house experience.

Mark Sullivan, Director of Medicines Development said “We are delighted to be working with Immuron. Gerhard’s placement is a direct result of Immuron’s innovative approach and the support we have received from Victorian Government to provide a very practical solution to new product development. Gerhard, Immuron and Medicines Development all benefit from this program focused on improving new product development across the sector.”

Joe Baini, Chief Executive Officer at Immuron said “We welcome Gerhrad to Immuron as a significant addition to our team. Gerhard’s knowledge and understanding of the complex regulatory environments in global markets will be pivotal as Immuron continues to licence Travelan around the world as well as establish a strong regulatory base for all future products emanating from our unique platform technology.”

ABOUT IMMURON LIMITED
Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).

For more information on Immuron Limited please visit the company’s website at www.immuron.com or call +61 3 8637 1107.